Filing summary
Period and issuer: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2013, filed September 17, 2013. This does not match the request metadata identifying Lite Strategy, Inc. and “2011 Q4”; the summary below reflects the filing text provided.
Business context
MEI Pharma is a development-stage oncology company with no commercialized products or operating revenue. Its lead candidate, Pracinostat, was in Phase II development; ME-344 was in a Phase I trial, and ME-143 was also in the pipeline. The company acquired Pracinostat-related assets from S*Bio in August 2012.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Operating revenue | None reported | None reported |
| Research and development expense | $6.084 million | $4.915 million |
| General and administrative expense | $5.138 million | $3.479 million |
| Net loss | $11.186 million | $7.523 million |
| Net cash used in operating activities | $10.044 million | $7.081 million |
| Cash and cash equivalents at year-end | $35.573 million | $6.202 million |
At June 30, 2013, total current assets were $36.029 million and current liabilities were $1.675 million; stockholders’ equity was $34.872 million. The balance sheet reports no borrowings or other debt. The company reported no off-balance-sheet arrangements. Profit margins are not meaningful because the company had no operating revenue and incurred a loss.
Financing provided $39.453 million in net cash during FY2013, including proceeds from a December 2012 private placement and an April 2013 stock offering. Shares outstanding rose substantially; the December placement also included warrants. Management believed available cash would fund operations for at least the next 12 months, while noting that further financing may be needed.
Changes and outlook
Compared with FY2012, net loss increased by $3.663 million, operating cash use increased by $2.963 million, and R&D expense increased by $1.169 million. Management attributed higher R&D costs principally to Pracinostat manufacturing and Phase II preparation, the ME-344 Phase I trial, and additional personnel. G&A rose by $1.659 million, including higher compensation and professional costs.
Management expected R&D expense to increase in FY2014, primarily due to planned Pracinostat Phase II trials. A blinded, placebo-controlled Phase II Pracinostat-plus-Vidaza trial in higher-risk MDS began in June 2013; enrollment completion was anticipated by June 2014 and topline results by December 2014. Two additional Phase II Pracinostat combination trials were planned. ME-344 trial results were expected in calendar Q4 2013. These are stated expectations, not assurances.
Risks and unusual items
- The company had accumulated losses of $96.297 million and anticipated continued operating losses and negative operating cash flow. Clinical success, regulatory approval, and commercialization were uncertain.
- Additional capital may be required; equity financing could dilute existing holders. At June 30, 2013, outstanding warrants covered approximately 5.1 million shares, in addition to options and restricted stock units.
- Clinical development depends on third-party trial operators and contract manufacturers; delays, safety findings, or unfavorable results could disrupt programs. The company had no commercial manufacturing capability.
- The S*Bio asset purchase included potential clinical, regulatory, and sales milestone payments of up to $75.2 million, plus sales-based earn-outs; no future amounts had been accrued at year-end. These payments are contingent.
- Pracinostat showed preliminary activity in earlier studies, including a small pilot MDS combination trial, but the filing cautions that early results may not predict later outcomes. ME-344 had reached dose-limiting toxicities at 20 mg/kg, with a maximum tolerated dose of 10 mg/kg.
- FY2012 included non-operating gains from derivative-liability fair-value adjustments; these did not recur in FY2013, so reported losses are affected by unusual prior-period items. The 1-for-6 reverse stock split and major equity financings also affect share-count comparisons.
Investor verification priorities
- Confirm the issuer and reporting period: this text is MEI Pharma’s FY2013 10-K, not a Lite Strategy filing or a 2011 Q4 report.
- Check subsequent cash use, financing, and share dilution against the stated 12-month runway, including warrant exercises and any later capital raises.
- Verify enrollment, trial status, safety, and reported results for the Pracinostat and ME-344 programs against later disclosures.
- Review the full S*Bio agreement and other contingent commitments, including milestone triggers, earn-out terms, and potential cash or share payments.
- Assess the reconciliation of FY2012 derivative-related gains and other nonrecurring items when comparing losses across years.